Showing 1183 results
- https://www.novartis.com/news/media-releases/novartis-kundigt-veranderungen-der-geschaftsleitungFelix R. Ehrat, Group General Counsel, tritt per 1. Juni 2018 zurück Shannon Thyme Klinger zum Group General Counsel ernannt Robert Weltevreden zum Leiter Novartis Business Services ernannt…
- https://www.novartis.com/news/media-releases/novartis-annonce-son-intention-de-solliciter-lapprobation-des-actionnaires-pour-la-scission-100-dalcon-sa-division-de-produits-ophtalmologiques-et-initie-un-rachat-dactions-hauteur-dusdL'examen stratégique d'Alcon conclut qu'une scission à 100% serait dans l'intérêt des actionnaires et en ligne avec la stratégie de Novartis visant à se concentrer sur son activité pharmaceutique…
- https://www.novartis.com/news/media-releases/novartis-presents-new-data-demonstrating-long-term-efficacy-safety-and-tolerability-aimovig-erenumab-patients-chronic-and-episodic-migraineResults from a one-year study of efficacy and safety of Aimovig in chronic migraine and data from a three-year analysis assessing safety and tolerability of Aimovig in episodic migraine will be…
- https://www.novartis.com/news/media-releases/novartis-international-ag-global-study-novartis-and-european-migraine-and-headache-alliance-reveals-60-employed-people-severe-migraine-miss-average-week-work-monthStudy reveals migraine causes significant disruption to daily life and work, which could be managed with better preventive treatments and workplace solutions Migraine is estimated to cost up to…
- https://www.novartis.com/news/media-releases/novartis-clear-about-psoriasis-survey-data-highlights-challenges-psoriasis-patients-face-achieve-goal-clear-skinSurvey data published in JEADV show that patients experienced four different treatments and three medical professionals on average before finding an efficacious therapy[1] New publication also…
- https://www.novartis.com/news/media-releases/novartis-international-ag-alcon-acrysof-iq-panoptix-trifocal-intraocular-lens-shows-superior-visual-performance-head-head-trial-post-cataract-surgeryBetter visual outcomes for patients with the AcrySof IQ PanOptix intraocular lens at near and intermediate distance vision[1] Detailed findings presented at World Ophthalmology Congress 2018…
- https://www.novartis.com/news/media-releases/novartis-juliet-trial-kymriah-demonstrates-more-one-year-durability-responses-adults-relapsed-or-refractory-dlbclOverall response rate was 52% and median duration of response was not reached at a median follow-up of 14 months, signifying responses were durable[1] Patients had a 65% chance of being…
- https://www.novartis.com/news/media-releases/novartis-survey-uncovers-real-world-impact-immune-thrombocytopenia-or-itp-rare-blood-disease-patients-quality-lifeFindings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%) About two-thirds of…
- https://www.novartis.com/news/media-releases/novartis-study-real-world-data-concludes-jakavi-associated-reduction-risk-death-and-dangerous-blood-clots-patients-rare-blood-cancerComparison of Jakavi® (ruxolitinib) vs. best available therapy presented at EHA suggests reduced risk of death in patients with inadequately controlled polycythemia vera (PV)[1] Additional…
- https://www.novartis.com/news/media-releases/sandoz-presents-new-long-term-and-switching-data-biosimilars-zessly-infliximab-and-erelzi-etanercept-rheumatoid-arthritisZessly® (infliximab) matched the reference medicine in terms of safety and efficacy at 54 weeks, even in patients who switched from the reference medicine to Zessly[1] Switching from the…
Pagination
- ‹ Previous page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- …
- 119
- › Next page